Psoriatic Arthritis Journal Articles

• Safety of IV Golimumab in RA, PsA, and AS A pooled analysis of data from three trials provides insight into the safety profile of IV golimumab for the treatment of these rheumatologic conditions.
  Arthritis Research & Therapy, May 18, 2022
• Drug Dosing in Hospitalized Obese Patients With COVID-19 When making dosing decisions for the treatment of hospitalized COVID-19 patients with obesity, weight and BMI should be considered.
  Critical Care, May 11, 2022
• Response Time for Outcomes in Psoriatic Arthritis Treatment When can a meaningful response be expected with psoriatic arthritis treatments? A better understanding could help guide treatment decisions.
  Arthritis Research & Therapy, April 11, 2022
• Predictive Diagnostic Criteria for Psoriasis in Children The clinical presentation of psoriasis often differs in children compared with adults. This paper proposes seven criteria for accurate diagnosis of psoriasis in children and young people.
  The British Journal of Dermatology, March 21, 2022
• Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology This review details the mechanism of action of JAK inhibitors and assesses their efficacy and safety in the treatment of a wide variety of dermatological conditions.
  Skin Therapy Letter, March 17, 2022
• Rheumatic Disease Flare-Up After SARS-CoV-2 mRNA Vaccine A new study finds a low incidence of disease flare-up after mRNA SARS-CoV-2 vaccines among rheumatic musculoskeletal disease patients.
  Arthritis Research & Therapy, March 16, 2022
• Safety and Efficacy of Tofacitinib for Ulcerative Colitis This paper presents final data from OCTAVE Open, an open-label, long-term extension study on the safety and efficacy of the Janus kinase inhibitor tofacitinib for the treatment of ulcerative colitis.
  Alimentary Pharmacology & Therapeutics, March 08, 2022
• Psoriasis-related Treatment, Hospitalization Due to COVID-19 Have systemic treatments for psoriasis been associated with an increased risk of hospitalization or in-hospital mortality due to COVID-19?
  The British Journal of Dermatology, February 07, 2022
• Association of Sex and Systemic Therapy Outcomes in Psoriasis Do antipsoriatic drugs work better in women than men? This study examines differences between men and women in their responses to systemic antipsoriatic treatment.
  The British Journal of Dermatology, January 11, 2022
• Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis The results of this study provide evidence that the IL-17 inhibitor secukinumab is effective in managing the concomitant features of psoriasis and psoriatic arthritis.
  The British Journal of Dermatology, January 04, 2022
• Patient Pathways to Diagnosis of Psoriatic Arthritis Gain a better understanding of the symptoms that may precede a psoriatic arthritis diagnosis and patients' experiences in obtaining the diagnosis.
  Arthritis Research & Therapy, December 14, 2021
• Malignancy Risk in Patients With Secukinumab-treated Psoriasis Does treatment with secukinumab increase the risk of malignancy in patients being treated for psoriasis, psoriatic arthritis, or ankylosing spondylitis?
  The British Journal of Dermatology, December 07, 2021
• Secukinumab as a Potential Trigger of IBD in AS or PsA Secukinumab is used to treat ankylosing spondylitis and psoriatic arthritis, but what do we know about the possible gastrointestinal-related adverse events?
  Rheumatology, December 01, 2021
• The Promise and Challenges of Cell Therapy for Psoriasis This review highlights the use of cell therapy for the management of immune-mediated inflammatory diseases and emerging evidence for its efficacy in severe psoriasis refractory to biological therapy.
  The British Journal of Dermatology, November 30, 2021
• Interpreting Cortisol and SSTs to Prevent Misdiagnosis of AI Cortisol levels taken at suboptimal times can lead to patients misdiagnosed with adrenal insufficiency and unnecessary treatments.
  Journal of the Endocrine Society, November 18, 2021
• Immune Checkpoint Inhibitor Treatment Toxicity Risk in RA A new analysis investigates the potential for patients with rheumatoid arthritis to experience adverse events after treatment with immune checkpoint inhibitors.
  Journal of Clinical Rheumatology, November 01, 2021
• Ustekinumab Maintenance Therapy in Ulcerative Colitis This study to assess the real-world effectiveness and safety of ustekinumab in patients with refractory ulcerative colitis confirms long-term effectiveness with a good safety profile.
  Alimentary Pharmacology & Therapeutics, October 20, 2021
• Mediterranean Diet in Axial Spondyloarthritis Patients with axial spondyloarthritis who adhere to a Mediterranean diet may realize improvements in disease activity, a new study suggests.
  Arthritis Research & Therapy, October 11, 2021
• Cardiovascular Safety of Biologics Targeting IL-12 or IL-23 Do the biologics briakinumab and ustekinumab, which target interleukin-12 and IL-23 in the treatment of psoriasis, increase the risk of cardiovascular disease?
  American Journal of Clinical Dermatology, September 24, 2021
• Does Methotrexate Influence Covid-19 Infection? Might treatment with methotrexate help lower the risk for developing COVID-19? A new study examines the possible protective effects of this drug.
  Arthritis Research & Therapy, July 26, 2021